WCLC: AstraZeneca heads for Roche battle with Imfinzi small-cell survival win
WCLC: AstraZeneca heads for Roche battle with Imfinzi small-cell survival win
Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera
Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera
Global Oncology Trends 2019 report
Global Oncology Trends 2019 report
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
Top 10 Immuno-Oncology Startups
Top 10 Immuno-Oncology Startups
Tumor Microenvironments Are Target-Rich Environments
Tumor Microenvironments Are Target-Rich Environments
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Humble Beginnings: The Origin Story of Modern Biotechnology
Humble Beginnings: The Origin Story of Modern Biotechnology
Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment
Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment
Lilly rushed its Loxo deal to have a big reveal at JPM
Lilly rushed its Loxo deal to have a big reveal at JPM
How Immunotherapy Could Stop and Prevent Type 1 Diabetes
How Immunotherapy Could Stop and Prevent Type 1 Diabetes
Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas
Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas
5 Biopharma Trends to Watch in 2019
5 Biopharma Trends to Watch in 2019
Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory
Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory
Experts Forecast Cancer Research and Treatment Advances in 2019
Experts Forecast Cancer Research and Treatment Advances in 2019
